1-3 of 3
Yarlagadda S. Babu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BCX9930, an Oral Factor D Inhibitor, for the Potential Treatment of Alternative Pathway Mediated Diseases: Interim Results of a Phase 1 Study in Healthy Subjects

Matthew Davidson, PharmD, Amanda Mathis, PhD, Stuart Mair, MBChB, DRCOG, DCPSA, FFPM, Diane Gesty-Palmer, MD PhD, Melanie Cornpropst, PharmD, PhD, William P. Sheridan, MBBS, Xilin Chen, MDPhD, David Reynolds, BS MT, Cynthia Parker, BS, Yarlagadda S. Babu, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-138475
Published: 2020
Journal Articles

Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH)

Xilin Chen, MDPhD, Xiaogang Cheng, PhD, Qingde Liu, PhD, Saritha Muppa, MS, Cynthia Parker, BS, Fugang Zhu, PhD, Krishnan Raman, PhD, Pravin L Kotian, PhD, Yarlagadda S. Babu, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32.
https://doi.org/10.1182/blood-2020-133921
Published: 2020
Journal Articles

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent.

Shanta Bantia, PhD, Cynthia Parker, Ramanda Upshaw, John Michael Kilpatrick, PhD, Amanda Cunningham, Jianwen Zhang, PhD, Pravin Kotian, PhD, Philip Morris, PhD, Pooran Chand, PhD, Yarlagadda S. Babu, PhD
Journal: Blood
Blood (2008) 112 (11): 1547.
https://doi.org/10.1182/blood.V112.11.1547.1547
Published: 2008